ARTELO BIOSCIENCES, INC. — Form 8-K
Filed August 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Artelo Biosciences implemented a 1-for-9 reverse stock split of common stock, effective August 31, 2026, reducing outstanding shares from approximately 4.93 million to 547,774 shares. The reverse split was executed to increase share price and improve marketability and liquidity. Shareholders' pro-rata ownership percentages remain unchanged; fractional shares convert to whole shares.
Why this rating
Reverse split is routine capital structure action; no fundamental business change, cash raised, or asset/liability shift. Signals stock price distress but does not alter company value or operations.
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.